TY  - JOUR
AU  - Navarro-Ocon, Alba
AU  - Blaya-Canovas, Jose L
AU  - Lopez-Tejada, Araceli
AU  - Blancas, Isabel
AU  - Sanchez-Martin, Rosario M
AU  - Garrido, María J
AU  - Griñan-Lison, Carmen
AU  - Calahorra, Jesus
AU  - Cara, Francisca E
AU  - Ruiz-Cabello, Francisco
AU  - Marchal, Juan A
AU  - Aptsiauri, Natalia
AU  - Granados-Principal, Sergio
PY  - 2022
DO  - 10.3390/pharmaceutics14030505
SN  - 1999-4923
UR  - http://hdl.handle.net/10668/21545
T2  - Pharmaceutics
AB  - Breast cancer is the most common type of malignancy and leading cause of cancer death among women worldwide. Despite the current revolutionary advances in the field of cancer immunotherapy, clinical response in breast cancer is frequently below...
LA  - en
PB  - MDPI AG
KW  - breast cancer
KW  - cancer immunotherapy
KW  - cancer treatment
KW  - immune escape
KW  - nanomedicine
KW  - Tumor Escape
KW  - Breast Neoplasms
KW  - Immune Evasion
KW  - Tumor Microenvironment
KW  - Immunotherapy
KW  - T-Lymphocytes
TI  - Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer.
TY  - research article
VL  - 14
ER  -